Enovis

Enovis shares trade at $18.17, a 52-week low, and are currently below InvestingPro’s fair-value estimate. Over the past year the price fell 42.24%, while the company reported adjusted earnings of $0.90 per share on revenue of $582.78 million for Q2 2026. Enovis announced the acquisition of eCential Robotics for about €176 million, which could create margin pressure and has prompted BMO and Citizens to cut their price targets. Analysts expect a return to profitability this year, but investors remain cautious due to the near-term outlook and cost pressures. » Więcej na de.investing.com

Enovis presented a robotics focus at the Wells Fargo conference and announced a planned acquisition of Amplitude Surgical in Q4 2026 to combine shoulder and knee robotics with its ARVIS platform. Management reports normalized demand in the US and slower but above-market growth in Europe, where Enovis is gaining market share. The acquisition is expected to weigh on margins and leverage in the near term (EBITDA margin -100 basis points, leverage temporarily ~3.5x) but to drive growth and technology integration over the long term. Enovis is targeting a free cash flow conversion rate of ~50% next year (about $100 million) and 70–80% by 2029; the US launch of the knee robot is planned for 2028. » Więcej na de.investing.com

Enovis shares hit a new 52-week low at $19.12, losing 18.65% just last week and down 39.14% year-to-date. Despite a surprising Q2 result (adjusted EPS $0.90 vs. $0.85 expected; revenue $582.78 million), a cautious outlook and ongoing cost pressures weigh on sentiment. Enovis announced the acquisition of eCential Robotics for about €176 million, prompting analysts to cut forecasts while largely maintaining positive ratings. Technical indicators on InvestingPro point to an oversold condition, which could present a contrarian buying opportunity. » Więcej na de.investing.com